Article Details
Retrieved on: 2021-04-21 07:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Roche has cut a series of experimental lung drugs from its pipeline, including two midstage COVID assets. The first drug, an Amgen-licensed anti-ST2 ...
Article found on: www.fiercebiotech.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here